X
Xian Jin Xie
Researcher at University of Iowa
Publications - 151
Citations - 8116
Xian Jin Xie is an academic researcher from University of Iowa. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 43, co-authored 140 publications receiving 7068 citations. Previous affiliations of Xian Jin Xie include University of Texas at Dallas & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
BAP1 loss defines a new class of renal cell carcinoma
Samuel Peña-Llopis,Silvia Vega-Rubin-de-Celis,Silvia Vega-Rubin-de-Celis,Arnold Liao,Nan Leng,Andrea Pavia-Jimenez,Andrea Pavia-Jimenez,Shanshan Wang,Shanshan Wang,Toshinari Yamasaki,Toshinari Yamasaki,Leah Zhrebker,Leah Zhrebker,Sharanya Sivanand,Sharanya Sivanand,Patrick Spence,Patrick Spence,Lisa N. Kinch,Tina Hambuch,Suneer Jain,Yair Lotan,Vitaly Margulis,Arthur I. Sagalowsky,Pia Banerji Summerour,Wareef Kabbani,S. W Wendy Wong,Nick V. Grishin,Marc Laurent,Xian Jin Xie,Christian D. Haudenschild,Mark T. Ross,David R. Bentley,Payal Kapur,James Brugarolas +33 more
TL;DR: The results establish the foundation for an integrated pathological and molecular genetic classification of RCC, paving the way for subtype-specific treatments exploiting genetic vulnerabilities.
Journal ArticleDOI
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen,Haley Hill,Alana Christie,Min Kim,Eboni Holloman,Andrea Pavia-Jimenez,Farrah Homayoun,Yuanqing Ma,Nirav V. Patel,Paul Yell,Guiyang Hao,Qurratulain Yousuf,Allison Joyce,Ivan Pedrosa,Heather Geiger,He Zhang,Jenny Chang,Kevin H. Gardner,Richard K. Bruick,Catherine Reeves,Tae Hyun Hwang,Kevin D. Courtney,Eugene P. Frenkel,Xiankai Sun,Naseem J. Zojwalla,Tai Wong,James P. Rizzi,Wallace Eli M,John A. Josey,Yang Xie,Xian Jin Xie,Payal Kapur,Renée M. McKay,James Brugarolas +33 more
TL;DR: It is shown that some ccRCCs are HIF-2 independent, and set the stage for biomarker-driven clinical trials, using a tumourgraft/patient-derived xenograft platform to evaluate PT2399, a selective Hif-2 antagonist that was identified using a structure-based design approach.
Journal ArticleDOI
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst,Brian O. Bodemann,Jessica Cardenas,Deborah A. Ferguson,Luc Girard,Michael Peyton,John D. Minna,C. H. Michnoff,Weihua Hao,Michael G. Roth,Xian Jin Xie,Michael A. White +11 more
TL;DR: It is shown that several of these targets sensitize lung cancer cells to paclitaxel concentrations 1,000-fold lower than otherwise required for a significant response, and mechanistic relationships between cancer-associated aberrant gene expression programmes and the basic cellular machinery required for robust mitotic progression are identified.
Journal ArticleDOI
Regulation of TFEB and V‐ATPases by mTORC1
Samuel Peña-Llopis,Silvia Vega-Rubin-de-Celis,Jacob C. Schwartz,Nicholas C. Wolff,Tram Anh T. Tran,Lihua Zou,Xian Jin Xie,David R. Corey,James Brugarolas +8 more
TL;DR: A regulatory network linking an oncogenic transcription factor that is a master regulator of lysosomal biogenesis, TFEB, to mTORC1 and endocytosis is uncovered.
Journal ArticleDOI
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation
Payal Kapur,Samuel Peña-Llopis,Alana Christie,Leah Zhrebker,Andrea Pavia-Jimenez,W. Kimryn Rathmell,Xian Jin Xie,James Brugarolas +7 more
TL;DR: The findings establish the basis for a molecular genetic classification of clear-cell renal-cell carcinoma with distinct clinical outcomes, a high-risk BAP1-mutant group and a favourable PBRM1-Mutant group.